Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli & Paolo Verdecchia. (2011) Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opinion on Drug Metabolism & Toxicology 7:1, pages 115-128.
Read now
Read now
Paolo Verdecchia, Fabio Angeli, Giovanni Mazzotta, Giorgio Gentile & Gianpaolo Reboldi. (2008) The renin angiotensin system in the development of cardiovascular disease: role of aliskiren in risk reduction. Vascular Health and Risk Management 4:5, pages 971-981.
Read now
Read now
Helmy Siragy, Jiqian Huang & David C Lieb. (2008) The development of the direct renin inhibitor aliskiren: treating hypertension and beyond. Expert Opinion on Emerging Drugs 13:3, pages 417-430.
Read now
Read now
Huifang Cheng & Raymond C Harris. (2006) Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers. Expert Opinion on Drug Safety 5:5, pages 631-641.
Read now
Read now
Jürgen Maibaum & David L Feldman. (2003) Renin inhibitors as novel treatments for cardiovascular disease. Expert Opinion on Therapeutic Patents 13:5, pages 589-603.
Read now
Read now
Naomi DL Fisher & Norman K Hollenberg. (2001) Is there a future for renin inhibitors?. Expert Opinion on Investigational Drugs 10:3, pages 417-426.
Read now
Read now
Peter Raddatz. (1994) Overview Cardiovascular & Renal: Recent developments in renin inhibitors: part 1. Expert Opinion on Therapeutic Patents 4:5, pages 489-504.
Read now
Read now
Articles from other publishers (56)
Jane Barber, Phumzile Sikakana, Claire Sadler, Delphine Baud, Jean-Pierre Valentin & Ruth Roberts. (2021) A target safety assessment of the potential toxicological risks of targeting plasmepsin IX/X for the treatment of malaria. Toxicology Research 10:2, pages 203-213.
Crossref
Crossref
Tomoya Hara, Takeshi Yamamura, Mirei Murakami‐Asahina, Hirokazu Matsumoto, Michiyasu Takeyama, Ray Kanagawa & Tomoyuki Nishimoto. (2020) Development of a novel murine heart failure model overexpressing human renin and angiotensinogen. FEBS Open Bio 10:5, pages 718-725.
Crossref
Crossref
Xingxing Li, Jing Liao, Zhongliang Jiang, Xinyu Liu, Shan Chen, Xia He, Ling Zhu, Xingmei Duan, Zhuyu Xu, Baowen Qi, Xiaoqiang Guo, Rongsheng Tong & Jianyou Shi. (2020) A concise review of recent advances in anti-heart failure targets and its small molecules inhibitors in recent years. European Journal of Medicinal Chemistry 186, pages 111852.
Crossref
Crossref
Tomoya Hara, Satoshi Nishimura, Toshihiro Yamamoto, Yumiko Kajimoto, Keiji Kusumoto, Ray Kanagawa, Shota Ikeda & Tomoyuki Nishimoto. (2018) TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model. PLOS ONE 13:8, pages e0202176.
Crossref
Crossref
Hidekazu Tokuhara, Yasuhiro Imaeda, Yoshiyuki Fukase, Koichi Iwanaga, Naohiro Taya, Koji Watanabe, Ray Kanagawa, Keisuke Matsuda, Yumiko Kajimoto, Keiji Kusumoto, Mitsuyo Kondo, Gyorgy Snell, Craig A. Behnke & Takanobu Kuroita. (2018) Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile. Bioorganic & Medicinal Chemistry 26:12, pages 3261-3286.
Crossref
Crossref
Lara McGillewie, Muthusamy Ramesh & Mahmoud E. Soliman. (2017) Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases. The Protein Journal 36:5, pages 385-396.
Crossref
Crossref
Estella G. da Mota, Mariene H. Duarte, Elaine F. F. da Cunha & Matheus P. Freitas. (2015) Theoretical design of new indole-3-carboxamide derivatives as renin inhibitors. Medicinal Chemistry Research 24:7, pages 3097-3106.
Crossref
Crossref
Holger Sellner, Sylvain Cottens, Frédéric Cumin, Claus Ehrhardt, Takatoshi Kosaka, Edwige Lorthiois, Nils Ostermann, Randy L. Webb, Dean F. Rigel, Trixie Wagner & Jürgen Maibaum. (2015) trans -3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: Prime site exploration using an oxygen linker. Bioorganic & Medicinal Chemistry Letters 25:8, pages 1787-1791.
Crossref
Crossref
Edwige Lorthiois, Frederic Cumin, Claus Ehrhardt, Takatoshi Kosaka, Holger Sellner, Nils Ostermann, Eric Francotte, Trixie Wagner & Jürgen Maibaum. (2015) trans -(3 S ,4 S )-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker. Bioorganic & Medicinal Chemistry Letters 25:8, pages 1782-1786.
Crossref
Crossref
Hitesh V. Motwani, Maria De Rosa, Luke R. Odell, Anders Hallberg & Mats Larhed. (2015) Aspartic protease inhibitors containing tertiary alcohol transition-state mimics. European Journal of Medicinal Chemistry 90, pages 462-490.
Crossref
Crossref
Stephen Hanessian, Etienne Chénard, Sébastien Guesné & Jean-Philippe Cusson. (2014) Conception and Evolution of Stereocontrolled Strategies toward Functionalized 8-Aryloctanoic Acids Related to the Total Synthesis of Aliskiren. The Journal of Organic Chemistry 79:20, pages 9531-9545.
Crossref
Crossref
Pitchai Balakumar & Gowraganahalli Jagadeesh. (2014) A century old renin–angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology. Cellular Signalling 26:10, pages 2147-2160.
Crossref
Crossref
F. T. HAMMAD, S. AL-SALAM & L. LUBBAD. (2013) Does Aliskiren Protect the Kidney Following Ischemia Reperfusion Injury?. Physiological Research, pages 681-690.
Crossref
Crossref
Edwige Lorthiois, Werner Breitenstein, Frederic Cumin, Claus Ehrhardt, Eric Francotte, Edgar Jacoby, Nils Ostermann, Holger Sellner, Takatoshi Kosaka, Randy L. Webb, Dean F. Rigel, Ulrich Hassiepen, Paul Richert, Trixie Wagner & Jürgen Maibaum. (2013)
The Discovery of Novel Potent
trans
-3,4-Disubstituted Pyrrolidine Inhibitors of the Human Aspartic Protease Renin from in Silico Three-Dimensional (3D) Pharmacophore Searches
. Journal of Medicinal Chemistry 56:6, pages 2207-2217.
Crossref
Crossref
Hans H. Gorris. (2013) Kinetic analysis of renin and its inhibitors by detecting double-labelled peptidic substrates with an immunoassay. The Analyst 138:7, pages 2104.
Crossref
Crossref
Tao Jing, Jian Feng, Yumei Zuo, Boli Ran, Jianping Liu & Guoxiang He. (2012) Exploring the substructural space of indole-3-carboxamide derivatives binding to renin: a novel active-site spatial partitioning approach. Journal of Molecular Modeling 18:9, pages 4417-4426.
Crossref
Crossref
Haralambos Tzoupis, Georgios Leonis, Grigorios Megariotis, Claudiu T. Supuran, Thomas Mavromoustakos & Manthos G. Papadopoulos. (2012) Dual Inhibitors for Aspartic Proteases HIV-1 PR and Renin: Advancements in AIDS–Hypertension–Diabetes Linkage via Molecular Dynamics, Inhibition Assays, and Binding Free Energy Calculations. Journal of Medicinal Chemistry 55:12, pages 5784-5796.
Crossref
Crossref
Aggeliki Politi , Georgios Leonis, Haralambos Tzoupis , Dimitrios Ntountaniotis, Manthos G. Papadopoulos, Simona Golic Grdadolnik & Thomas Mavromoustakos . (2011) Conformational Properties and Energetic Analysis of Aliskiren in Solution and Receptor Site. Molecular Informatics 30:11-12, pages 973-985.
Crossref
Crossref
Lanqi Jia, Robert D. Simpson, Jing Yuan, Zhenrong Xu, Wei Zhao, Salvacion Cacatian, Colin M. Tice, Joan Guo, Alexey Ishchenko, Suresh B. Singh, Zhongren Wu, Brian M. McKeever, Yuri Bukhtiyarov, Judith A. Johnson, Christopher P. Doe, Richard K. Harrison, Gerard M. McGeehan, Lawrence W. Dillard, John J. Baldwin & David A. Claremon. (2011) Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility. ACS Medicinal Chemistry Letters 2:10, pages 747-751.
Crossref
Crossref
Louis-Charles Campeau, Sarah J. Dolman, Danny Gauvreau, Ed Corley, Jinchu Liu, Erin N. Guidry, Stéphane G. Ouellet, Dietrich Steinhuebel, Mark Weisel & Paul D. O’Shea. (2011) Convergent Kilo-Scale Synthesis of a Potent Renin Inhibitor for the Treatment of Hypertension. Organic Process Research & Development 15:5, pages 1138-1148.
Crossref
Crossref
Bodo Scheiper, Hans Matter, Henning Steinhagen, Zsolt Böcskei, Valérie Fleury & Gary McCort. (2011) Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors. Bioorganic & Medicinal Chemistry Letters 21:18, pages 5480-5486.
Crossref
Crossref
Hans Matter, Bodo Scheiper, Henning Steinhagen, Zsolt B?cskei, Val?rie Fleury & Gary McCort. (2011) Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. Bioorganic & Medicinal Chemistry Letters 21:18, pages 5487-5492.
Crossref
Crossref
Carmela Molinaro, Scott Shultz, Amélie Roy, Stephen Lau, Thao Trinh, Rémy Angelaud, Paul D. O’Shea, Stefan Abele, Mark Cameron, Ed Corley, Jacques-Alexis Funel, Dietrich Steinhuebel, Mark Weisel & Shane Krska. (2011) A Practical Synthesis of Renin Inhibitor MK-1597 (ACT-178882) via Catalytic Enantioselective Hydrogenation and Epimerization of Piperidine Intermediate. The Journal of Organic Chemistry 76:4, pages 1062-1071.
Crossref
Crossref
Yuji Nakamura, Chie Suzuki, Teppei Fujimoto, Shojiro Miyazaki, Kazuhiko Tamaki, Takahide Nishi & Hiroshi Suemune. (2011) Efficient Synthesis of 5-Amino-6-dialkylamino-4-hydroxypentanamide Derivatives for Renin Inhibitors. HETEROCYCLES 83:7, pages 1587.
Crossref
Crossref
Christian Sund, Oscar Belda, Daniel Wiktelius, Christer Sahlberg, Lotta Vrang, Susanne Sedig, Elizabeth Hamelink, Ian Henderson, Tatiana Agback, Katarina Jansson, Neera Borkakoti, Dean Derbyshire, Anders Eneroth & Bertil Samuelsson. (2011) Design and synthesis of potent macrocyclic renin inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, pages 358-362.
Crossref
Crossref
Pitchai Balakumar & Gowraganahalli Jagadeesh. (2010) Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System. Journal of Cardiovascular Pharmacology 56:5, pages 570-579.
Crossref
Crossref
Bodo Scheiper, Hans Matter, Henning Steinhagen, Ulrich Stilz, Zsolt Böcskei, Valérie Fleury & Gary McCort. (2010) Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors. Bioorganic & Medicinal Chemistry Letters 20:21, pages 6268-6272.
Crossref
Crossref
Donald J. AbrahamColin M. Tice, Gerard M. McGeehan & David A. Claremon. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
239
266
.
Stephen Hanessian, Sébastien Guesné & Etienne Chénard. (2010) Total Synthesis of “Aliskiren”: The First Renin Inhibitor in Clinical Practice for Hypertension. Organic Letters 12:8, pages 1816-1819.
Crossref
Crossref
Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Tatsuya Narita, Kenichiro Kinouchi, Kanako Bokuda & Hiroshi Itoh. (2010) New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren. Journal of Pharmacological Sciences 113:4, pages 296-300.
Crossref
Crossref
Alan H. Gradman & Rishi Kad. (2008) Renin Inhibition in Hypertension. Journal of the American College of Cardiology 51:5, pages 519-528.
Crossref
Crossref
G T McInnes. (2007) Renin inhibition: the holy grail of renin–angiotensin system blockade?. Journal of Human Hypertension 21:10, pages 766-769.
Crossref
Crossref
Norman K Hollenberg. (2016) Spotlight on Renin. Journal of the Renin-Angiotensin-Aldosterone System 6:2, pages 107-109.
Crossref
Crossref
Naomi D.L. Fisher & Norman K. Hollenberg. (2005) Renin Inhibition: What Are the Therapeutic Opportunities?. Journal of the American Society of Nephrology 16:3, pages 592-599.
Crossref
Crossref
Jeanette M Wood, Christian R Schnell, Frederic Cumin, Jo??l Menard & Randy L Webb. (2005) Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. Journal of Hypertension 23:2, pages 417-426.
Crossref
Crossref
Rolf Henning. 2003. Organic Synthesis Set. Organic Synthesis Set
250
259
.
Mohammad Amin Zaman, Suzanne Oparil & David A. Calhoun. (2002) Drugs targeting the renin–angiotensin–aldosterone system. Nature Reviews Drug Discovery 1:8, pages 621-636.
Crossref
Crossref
Norman K. Hollenberg. (2000) Implications of Species Difference for Clinical Investigation. Hypertension 35:1, pages 150-154.
Crossref
Crossref
Rolf Henning. 1995. Organic Synthesis Highlights II. Organic Synthesis Highlights II
250
259
.
Naomi D. L. Fisher & Norman Hollenberg. (1995) Renal vascular responses to renin inhibition with zankiren in men*. Clinical Pharmacology & Therapeutics 57:3, pages 342-348.
Crossref
Crossref
N D FisherD AllanI KiforC L GabouryG H WilliamsT J MooreN K Hollenberg. (1994) Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.. Hypertension 23:1, pages 44-51.
Crossref
Crossref
Sherin S. Abdel‐Meguid. (2006) Inhibitors of Aspartyl Proteinases. Medicinal Research Reviews 13:6, pages 731-778.
Crossref
Crossref
E AlteriG BoldR CozensA FaesslerT KlimkaitM LangJ LazdinsB PoncioniJ L RoeselP Schneider. (1993) CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity. Antimicrobial Agents and Chemotherapy 37:10, pages 2087-2092.
Crossref
Crossref
M.T. Wu, T.J. Ikeler, W.T. Ashton, R.S.L. Chang, V.J. Lotti & W.J. Greenlee. (1993) Synthesis and structure-activity relationships of a novel series of non-peptide AT2-selective angiotensin II receptor antagonists. Bioorganic & Medicinal Chemistry Letters 3:10, pages 2023-2028.
Crossref
Crossref
J P ClozelW Fischli. (1993) Comparative effects of three different potent renin inhibitors in primates.. Hypertension 22:1, pages 9-17.
Crossref
Crossref
Daljit S. Dhanoa, William H. Parsons, William J. Greenlee & Arthur A. Patchett. (1992) The synthesis of potent marcocyclic renin inhibitors. Tetrahedron Letters 33:13, pages 1725-1728.
Crossref
Crossref
R.A. Rivero & W.J. Greenlee. (1991) The synthesis of novel macrocyclic inhibitors of human renin. Tetrahedron Letters 32:22, pages 2453-2456.
Crossref
Crossref
P CorderoN D FisherT J MooreR GleasonG H WilliamsN K Hollenberg. (1991) Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.. Hypertension 17:4, pages 510-516.
Crossref
Crossref
JOHN D. BAXTER, KEITH DUNCAN, WILLIAM CHU, MICHAEL N.G. JAMES, ROBERT B. RUSSELL, MOHAMMAD A. HAIDAR, FRANCES M. DENOTO, WILLA HSUEH & TIMOTHY L. REUDELHUBER. 1991. Proceedings of the 1990 Laurentian Hormone Conference. Proceedings of the 1990 Laurentian Hormone Conference
211
258
.
. (2010) Synthese hydroxyethylenisosterer Dipeptide. Nachrichten aus Chemie, Technik und Laboratorium 38:4, pages 460-464.
Crossref
Crossref
William J. Greenlee. (2006) Renin inhibitors. Medicinal Research Reviews 10:2, pages 173-236.
Crossref
Crossref
R. Henning, A. Wagner & B. A. Schölkens. 1990. Pharmacology of Antihypertensive Therapeutics. Pharmacology of Antihypertensive Therapeutics
483
505
.
M Gasparo, F Cumin, J Nussberger, TT Guyenne, JM Wood & J Menard. (1989) Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers.. British Journal of Clinical Pharmacology 27:5, pages 587-596.
Crossref
Crossref
K. G. Hofbauer & J. M. Wood. (1988) Renin inhibitors as possible antihypertensive agents. Klinische Wochenschrift 66:18, pages 906-913.
Crossref
Crossref
John J. Baldwin & Charles S. Sweet. 1988.
59
68
.
Joshua Boger. (1987) Clinical goal in sight for small molecule renin inhibitors. Trends in Pharmacological Sciences 8:10, pages 370-372.
Crossref
Crossref